These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 24222656)

  • 21. Renin inhibition--benefit beyond hypertension control.
    Kher V
    J Assoc Physicians India; 2009 Jul; 57():518-20, 525. PubMed ID: 20329413
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Renin inhibition and the kidney].
    Ecder T
    Turk Kardiyol Dern Ars; 2009 Oct; 37 Suppl 7():28-31. PubMed ID: 20019474
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improving microvascular outcomes in patients with diabetes through management of hypertension.
    McGill JB
    Postgrad Med; 2009 Mar; 121(2):89-101. PubMed ID: 19332966
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Newer renin-angiotensin-aldosterone system blocker combinations: is there an advantage?
    Lazich I; Bakris GL
    Curr Opin Nephrol Hypertens; 2011 Sep; 20(5):471-5. PubMed ID: 21709549
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Angiotensin-converting enzyme inhibitors in hypertension: a review.
    Salvetti A; Pedrinelli R; Arzilli F; Abdel-Haq B; Magagna A; Lucarini A; Graziadei L; Nuccorini A; Taddei S
    Int J Clin Pharmacol Res; 1985; 5(6):429-38. PubMed ID: 3005182
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Direct renin inhibitor aliskiren in the treatment of cardiovascular and renal diseases].
    Horký K
    Vnitr Lek; 2010 Feb; 56(2):120-6. PubMed ID: 20329582
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dual blockade of the renin-angiotensin-aldosterone system: beyond the ACE inhibitor and angiotensin-II receptor blocker combination.
    Bomback AS; Toto R
    Am J Hypertens; 2009 Oct; 22(10):1032-40. PubMed ID: 19661925
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aminopeptidase A, which generates one of the main effector peptides of the brain renin-angiotensin system, angiotensin III, has a key role in central control of arterial blood pressure.
    Reaux A; Iturrioz X; Vazeux G; Fournie-Zaluski MC; David C; Roques BP; Corvol P; Llorens-Cortes C
    Biochem Soc Trans; 2000; 28(4):435-40. PubMed ID: 10961935
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Direct inhibition of renin: a physiological approach to treat hypertension and cardiovascular disease.
    Ram CV
    Future Cardiol; 2009 Sep; 5(5):453-65. PubMed ID: 19715410
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The biochemical pharmacology of renin inhibitors: implications for translational medicine in hypertension, diabetic nephropathy and heart failure: expectations and reality.
    Abassi Z; Winaver J; Feuerstein GZ
    Biochem Pharmacol; 2009 Oct; 78(8):933-40. PubMed ID: 19477166
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Renin inhibition for hypertension: selecting the right role for a new class of drug.
    Bergset J; Storozynsky E; Bisognano JD
    Am J Ther; 2010; 17(2):182-7. PubMed ID: 19433972
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Direct renin inhibition with aliskiren in hypertension and target organ damage.
    Müller DN; Luft FC
    Clin J Am Soc Nephrol; 2006 Mar; 1(2):221-8. PubMed ID: 17699210
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Angiotensin-II receptor antagonists: a new class of antihypertensive agents.
    Weir MR
    Am Fam Physician; 1996 Feb; 53(2):589-94. PubMed ID: 8629540
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Emerging drugs which target the renin-angiotensin-aldosterone system.
    Steckelings UM; Paulis L; Unger T; Bader M
    Expert Opin Emerg Drugs; 2011 Dec; 16(4):619-30. PubMed ID: 21905943
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aliskiren, the future of renin-angiotensin system blockade?
    Uresin Y; Mehtar Bozkurt M; Sabirli S; Ozunal ZG
    Expert Rev Cardiovasc Ther; 2007 Sep; 5(5):835-49. PubMed ID: 17867914
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evolving role of aldosterone blockers alone and in combination with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in hypertension management: a review of mechanistic and clinical data.
    Black HR
    Am Heart J; 2004 Apr; 147(4):564-72. PubMed ID: 15077068
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aliskiren: an oral renin inhibitor for the treatment of hypertension.
    Lam S; Choy M
    Cardiol Rev; 2007; 15(6):316-23. PubMed ID: 18090068
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New approaches to blockade of the renin-angiotensin-aldosterone system: mineralocorticoid-receptor blockers exert antihypertensive and renoprotective effects independently of the renin-angiotensin system.
    Nishiyama A; Hasegawa K; Diah S; Hitomi H
    J Pharmacol Sci; 2010; 113(4):310-4. PubMed ID: 20675957
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [New strategy in the treatment of hypertension: inhibition of renin-angiotensin-aldosterone system with renin inhibitor].
    Pál L; Kalina A
    Orv Hetil; 2006 Apr; 147(17):785-9. PubMed ID: 16780186
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The renin-angiotensin-aldosterone system: focus on its distinct role in arterial hypertension and its various inhibitors as a therapeutic strategy to effectively lower blood pressure.
    Soldner A; Spahn-Langguth H; Mutschler E
    Pharmazie; 1996 Nov; 51(11):783-99. PubMed ID: 8985974
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.